BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served by strong leadership that respects and advances science, nutrition and medicine and ensures that the United States and our allies continue to lead the world in biotechnology. Indeed, the rich tradition of ‘gold-standard scientific research’ and ‘evidence-based science’ have always been at the core of our life-saving work to prevent, control and cure disease—and to provide access to healthy food security for all. This is the mission of America’s biotechnology companies. I have every confidence that we will continue to thrive and deliver on this important mission ahead. The world cannot wait. We look forward to working closely with President-elect Trump, his incoming Administration, and members of Congress on both sides of the aisle to achieve these mutual goals.” About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This promising update supports the latest advancements in science and biotechnology, encouraging innovation across a broader range of agricultural products. This progress toward aligning regulations with conventional breeding methods helps ensure that new, safe products can be brought to market more swiftly and efficiently, benefiting consumers and supporting sustainable agriculture.“BIO played a key role in urging the agency to consider these exemptions and believes these modifications will enable not only major biotech firms but also smaller businesses and academic institutions to drive cutting-edge agricultural development, benefiting both the U.S. economy and global food security.“This inclusion of stakeholder input—considering nearly 6,500 comments—is a testament to APHIS’ commitment to transparency and collaboration. BIO looks forward to working with the agency to further reduce barriers for innovators and expand the diversity of crops developed through biotechnology.” About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient and appropriate under the statute," said BIO's EVP for Health and Policy Programs, Phyllis Arthur. "A 340B rebate is, and should be, among the legally permissible options. We strongly support efforts that could bring the type of transparency needed to protect the integrity of the program.”A copy of BIO's prior letter to HRSA is available here: https://www.bio.org/letters-testimony-comments/bio-letter-hrsa-340b-rebate-model About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.